Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease
Laura Sepp-Lorenzino, Ph.D., Executive Vice President, Chief Scientific Officer, Intellia Therapeutics Laura Sepp-Lorenzino, Ph.D....
top of page
NEWS BLOG
Search
Gaëlle Jamar
- Nov 29, 2022
- 1 min
Safety considerations in therapeutic genome editing
Toni Cathomen, University of Freiburg Toni Cathomen is Director of the Institute for Transfusion Medicine and Gene Therapy at the Medical...
3 views
Gaëlle Jamar
- Nov 29, 2022
- 1 min
Repurposing of bacterial CRISPR-Cas immunity for genome editing
Virgis Siksnys, Vilnius University, Institute of Biotechnology Video available to ESGCT members only Virginijus Siksnys studied chemistry...
3 views
bottom of page